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The purpose of this study was to develop a two-compartment metabolic model of brain metabolism
to assess oxidative metabolism from [1-11C] acetate radiotracer experiments, using an approach
previously applied in 13C magnetic resonance spectroscopy (MRS), and compared with an one-
tissue compartment model previously used in brain [1-11C] acetate studies. Compared with 13C MRS
studies, 11C radiotracer measurements provide a single uptake curve representing the sum of all
labeled metabolites, without chemical differentiation, but with higher temporal resolution. The
reliability of the adjusted metabolic fluxes was analyzed with Monte-Carlo simulations using
synthetic 11C uptake curves, based on a typical arterial input function and previously published
values of the neuroglial fluxes Vtca
g , Vx, Vnt, and Vtca
n measured in dynamic 13C MRS experiments.
Assuming Vx
g = 10Vtcag and Vxn =Vtcan , it was possible to assess the composite glial tricarboxylic acid
(TCA) cycle flux Vgt
g (Vgt
g =Vx
gVtcag /(Vxg +Vtcag )) and the neurotransmission flux Vnt from 11C tissue-
activity curves obtained within 30 minutes in the rat cortex with a beta-probe after a bolus infusion of
[1-11C] acetate (n= 9), resulting in Vgt
g = 0.136±0.042 and Vnt = 0.170±0.103 lmol/g per minute
(mean±s.d. of the group), in good agreement with 13C MRS measurements.
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Introduction
The brain meets its energetic demands at rest and
during activation largely, if not exclusively by
oxidative combustion of fuels. The tricarboxylic
acid (TCA) cycle is central to oxidative cerebral
metabolism and its metabolic rate is thus particularly
important to measure when studying brain energetic
needs under different physiological conditions. In
addition to the generation of energy for brain cells
ultimately in the form of high-energy phosphates
such as ATP, the TCA cycle is involved in the
metabolism of amino acids, such as the major
excitatory neurotransmitter glutamate.
The major substrate for brain metabolism is
glucose. However, a limitation in the use of labeled
glucose or analogs to study brain metabolism is that
these tracers must pass through the glycolysis before
reaching the TCA cycle and do not reflect directly
TCA cycle activity. Deoxyglucose derivates, such as
the most frequently used fluorodeoxyglucose (FDG)
do not even enter the glycolysis. They are trapped
after phosphorylation by hexokinase to (fluoro-
deoxy)-glucose-6-phosphate and thus cannot reflect
oxidative metabolism. A solution is to use a direct
TCA cycle precursor, entering the metabolic pathway
after the glycolytic branch point. Acetate, which is
metabolized to acetyl-CoA and enters the TCA cycle
through citrate synthetase, similarly to pyruvate, is
an example of such a precursor.
Moreover, the compartmentation of glutamate
metabolism in brain opens the way to in vivo studies
of neuroglial interaction, using glial- or neuronal-
specific substrates, or tracers metabolized simulta-
neously by both cells. In contrast to glucose, acetate
is uniquely metabolized in the glial compartment
(Waniewski and Martin, 1998) and turns out to be an
ideal substrate to probe glial oxidative metabolism
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and to increase the sensitivity of the measurement
of the glutamate-glutamine cycle (de Graaf et al,
2003b; Henry et al, 2006). Labeled with the positron
emitting carbon-11, [1-11C] acetate is thus a suitable
substrate to assess glial oxidative metabolism and
local neurotransmission using positron emission
tomography (PET) or beta-probes (Wyss et al, 2009,
2011). However, to date, no metabolic model has been
presented to analyze brain [1-11C] acetate studies,
based on the biochemical reactions involved in
acetate utilization (e.g., TCA cycles, glutamate-gluta-
mine cycle). The aim of this study was to develop a
kinetic model for brain [1-11C] acetate infusion
experiments, based on the modeling methods used
for Nuclear Magnetic Resonance spectroscopy, com-
patible with the analysis of data acquired with PET
or beta-probe (Weber et al, 2003). The model was
evaluated on experimental data acquired with a beta-
probe in vivo in rat brains, after an intravenous bolus
injection of [1-11C] acetate.
Materials and methods
Beta-Probe Measurements
The metabolic model presented in this study was devel-
oped and tested with in vivo experimental data from [1-11C]
acetate infusion studies, obtained from the PET center in
Zurich and published elsewhere (Wyss et al, 2009). Data
were acquired in urethane anesthetized Sprague-Dawley
rats. All animal experiments were approved by the
veterinary authorities of the Canton of Zurich and were
performed in accordance with their guidelines. The
experiments were performed by licensed investigators.
Briefly, a dedicated b-scintillator (Swisstrace, Zurich,
Switzerland) was carefully inserted into the cortex at a
depth of B1.4mm below the dura avoiding large blood
vessels. With the 11C nuclide, the probe measures the local
radioactivity density of the tissue over time in a detection
sphere of B2mm of radius yielding tissue-activity curves
(Pain et al, 2002).
To measure the arterial input function (AIF) after bolus
injection of 230 to 260MBq of [1-11C] acetate, an arterio-
venous shunt from the right femoral artery to the right
femoral vein was used in conjunction with a g coincidence
counter to measure whole blood radioactivity. Data were
acquired during a minimum of 20 minutes, both for the
AIF and the brain tissue activity. The input function had
a time resolution of 2 seconds, while each beta-probe meas-
urement was averaged over 50 seconds.
Standard One-Tissue Compartment Model
A previous model for brain studies is the one-tissue
compartment model originally developed for 11C-acetate
cardiac studies (Buck et al, 1991). This model, composed of
two pools, is provided for completeness in Figure 1A. The
first pool represents acetate radioactivity concentration in
the plasma, known as AIF. The second pool represents the
total brain tissue activity. This pool is the sum of the activity
concentrations of all labeled metabolites. The rate of label
transfer between the two pools is typically calculated from
the first-order rate constants K1 and k2, representing the
uptake of 11C-acetate and the clearance of 11C through the
molecules resulting from brain metabolism of acetate
(predominantly 11CO2), respectively (Wyss et al, 2009).
The measured total activity curve includes the tissue
compartment and the vascular compartment. The vascular
volume fraction or cerebral blood volume (CBV) in the rat
cerebral cortex is on the order of 2% to 3% (Todd et al,
1993a; Weeks et al, 1990). The experimental curve is,
therefore, fitted to a linear combination of the two pools:
CmeasuredðtÞ ¼ 1 að ÞCtissueðtÞ þ a CplasmaðtÞ
where a corresponds to the relative CBV. Using the
measured AIF, the model was fitted to the tissue-activity
curve by varying the three parameters K1, k2, and a. The
plot in Figure 1C shows a systematic deviation of residuals
from zero, which was consistently observed with most
experimental data.
Neuroglial Model
In this study, metabolic modeling was developed using
a compartmentalized neurotransmitter approach previ-
ously applied in 13C Nuclear Magnetic Resonance studies
(Gruetter et al, 2001). Brain tissue is mainly composed of
glial and neuronal cells. It is now well accepted that glial
cells are actively involved in excitatory neurotransmission,
Figure 1 (A) One-tissue model of acetate metabolism originally
developed for 11C-acetate cardiac studies (Buck et al, 1991).
(B) Typical result obtained using this model on brain beta-probe
data. (C) The residuals show an unsatisfactory modeling of the
experimental data, suggesting a more complex dynamics. CBV,
cerebral blood volume.
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e.g., through the uptake of the neurotransmitter glutamate
from the synaptic cleft (Arriza et al, 1994). The model,
therefore, consists of two main metabolic compartments
corresponding to the two cell types. Each compartment
consists of the respective TCA cycle as well as of the
glutamate-glutamine cycle, linking the metabolism of both
compartments.
Acetate is almost exclusively metabolized in astrocytes
(glial compartment) (Lebon et al, 2002; Waniewski and
Martin, 1998). As a consequence, the inflow of new label
from the substrate is occurring only through the glial TCA
cycle. Nevertheless, the neuronal TCA cycle rate was
accounted for, since it provides unlabeled carbons originat-
ing from neuronal pyruvate metabolism to the glutamate-
glutamine cycle, which affects overall tissue activity.
The resulting model is presented in Figure 2A. To
illustrate how label is transferred within a molecule in
the TCA cycle, we added the detailed scheme in Figure 2B.
11C from [1-11C] acetate enters the glial TCA cycle at the
position 5 of citrate. Pyruvate metabolism in the glial
compartment dilutes the acetyl-CoA pool. In the first turn
of the TCA cycle, 11C reaches the position 5 of 2-oxoglu-
tarate with a total net flux KdilVtcag (Supplementary
Appendix A), where Kdil represents the affinity of glial
metabolism to acetate. Kdil was fixed to 0.76, as found in
13C
magnetic resonance spectroscopy (MRS) rat studies, in
similar physiological conditions (Duarte et al, 2011).
2-Oxoglutarate exchanges label with cytosolic glutamate.
This transmitochondrial label exchange, denoted by Vx
g,
transfers label from the carbon position 5 of 2-oxoglutarate
to the position 5 of glutamate. Due to the symmetry of the
succinate molecule, the second turn of the TCA cycle brings
half of the labeled carbons of the position 5 of 2-oxoglu-
tarate to the position 1 of 2-oxoglutarate and half of it is
eliminated as CO2. Through the transmitochondrial flux V
g
x,
[1-11C] glutamate is formed from [1-11C] 2-oxoglutarate. In
glia, metabolic pathways involving aspartate were assumed
to be negligible (Wurdig and Kugler, 1991).
On the neuronal side, label entering the TCA cycle in the
first turn from acetate is neglected, consistent with the
glial-specific uptake of acetate. Nevertheless, once neuro-
nal glutamate is sufficiently labeled by the action of the
glutamate-glutamine cycle (Vnt), the exchange between
glutamate and 2-oxoglutarate through Vnx allows in princi-
ple a labeling of the glutamate at position 1 from the
glutamate at position 5 in the second turn of the TCA cycle.
The fractional enrichments (concentration of labeled
molecules divided by the total concentration of this
molecule in the pool) of the neuronal glutamate pools are
expected to be low, because acetate is entering only on the
glial side and because the infusion experiments are short
(20 minutes in Wyss et al, 2009) on the time scale of
neuronal glutamate turnover times. Therefore, the labeling
of aspartate through the malate–aspartate shuttle on the
neuronal side was assumed to be negligible.
Carbon Dioxide Labeling
In radiotracer experiments, the measured radioactivity
curve represents all labeled compounds. Therefore, the
contribution to the total tissue activity of labeled CO2,
present in high concentrations of B13.8 to 15.1 mmol/g in
the brain (Thompson and Brown, 1960; Thompson et al,
1980), needs to be additionally taken into account. For the
modeling of CO2 labeling, we assumed a typical value of
15 mmol/g of total brain CO2, which includes bicarbonate,
in rapid exchange with CO2 due to the action of carbonic
anhydrase.
The input of label into the CO2 pool originates from both
glial and neuronal TCA cycles. In fact, two CO2 molecules
are released per turn in the TCA cycle (Figure 2B). An
additional CO2 molecule is produced in the glycolysis for
both compartments. Using the metabolic steady-state
assumption for CO2, the efflux of the CO2 pool Vout is:
Vout ¼ 3Vgtca þ 3Vntca
When infusing C1-labeled acetate, the first release of
label to CO2 occurs in decarboxylation of oxalosuccinate in
the second TCA cycle turn. Since 2-oxoglutarate can
exchange its carbon chain with glutamate, this label loss
originates either from acetate or from glutamate C5. The
second loss of labeled carbon to CO2 occurs in decarbox-
ylation of 2-oxoglutarate, also in the second TCA cycle
turn. This labeled carbon can originate directly from an
exchange with glutamate C1, from glutamate C5 or acetate.
Thus, CO2 can also be labeled from the neuronal
TCA cycle, but only from neuronal glutamate C5 and C1,
which both are likely to be only weakly labeled, since
acetate does not directly enter neurons. The third CO2
molecule produced in the glycolysis is unlabeled in both
compartments. The relative contribution of each of these
pools to CO2 labeling is elaborated in Supplementary
Appendix B.
CO2 diffuses almost freely across the blood–brain barrier.
It was estimated (Supplementary Appendix B) that the
total amount of CO2 in blood, considering all the transport
modes (dissolved, buffered with water as bicarbonate,
bound to proteins, particularly hemoglobin), is similar to
brain CO2 concentration (Pocock and Richards, 2004).
Assuming a fast exchange between these modes compared
with brain metabolism (Geers and Gros, 2000) and a
cerebral blood flow in the range of 1.3mL/g per minute
(Todd et al, 1993a, b), an influx of 20 mmol/g per minute of
unlabeled CO2 is estimated. This flux is large compared
with the TCA cycle fluxes and reduces the 11CO2 activity
and, therefore, its contribution to the total tissue-activity
curve. Including the 11CO2 pool introduces an additional
differential equation to the existing differential system, but
no extra parameter (flux) to adjust.
Units of the Data and Derived Fluxes
Positron emission data are measured in kBq/mL and not
directly as a concentration (in mmol/g). They are corrected
for radioactive decay and delay between the plasma
measurement and brain measurement due to blood circula-
tion. The Nuclear Magnetic Resonance metabolic modeling
approach expresses the total concentration of metabo-
lites (labeled or not) in mmol/g and the labeling of each
chemical pool in terms of fractional or isotopic enrichment
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Figure 2 (A) Schematic view of the compartmental metabolic model used for brain [1-11C] acetate metabolism. The diagram shows
the 11C labeling flows from acetate to the positions 5 and 1 of glutamate, glutamine and to CO2, through the glial and neuronal
tricarboxylic acid (TCA) cycles. (B) Detailed view of the carbon labeling flow through the glial TCA cycle. The neuronal TCA cycle is
similar, except that no carbon coming from acetate enters the neuronal TCA cycle. The colors enable the follow-up of the carbons
from one molecule to the next. The arrows on the right show how carbons are moving in the carbon chain of 2-oxoglutarate from one
TCA cycle turn to the next. The carbons 4 and 5 of citrate are always coming from acetyl-CoA. The carbon positions of glutamate (and
glutamine) are identical to those of 2-oxoglutarate. Two carbons are lost in CO2 at the level of oxalosuccinate and 2-oxoglutarate in
each TCA cycle turn.
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(Uffmann and Gruetter, 2007). For this study, standard total
concentrations of 3.5mmol/g for glutamine, 1mmol/g for
glial glutamate, and 8mmol/g for neuronal glutamate were
assumed (Kunz et al, 2010; Xin et al, 2010).
However, a conversion of the data from kBq/mL to mmol/g
was not necessary, since we are dealing with linear differ-
ential equations (see Supplementary Appendix A) in which
both beta-probe data and AIF are given in kBq/mL.
Using absolute concentrations in mmol/g for the chemical
pool sizes allows determining metabolic fluxes between
the pools in mmol/g per minute from the adjusted rate
constants. To solve the differential system, the fractional
enrichment of plasma acetate (AIF) was calculated assum-
ing a typical blood acetate concentration of 1 mmol/g in the
rat (Cetin et al, 2003).
Model Analysis
First, the standard one-tissue compartment model (Figure
1A) was applied to different tissue-activity time courses
acquired in vivo.
To assess the validity of the suggested new modeling
approach, the two-compartmental (neuroglial) model was
then implemented and studied under four different sets of
assumptions, further described below.
A system of linear differential equations was derived for
the neuroglial model, assuming metabolic steady-state (i.e.,
no net metabolite concentration changes are occurring).
As previously shown (Uffmann and Gruetter, 2007), the
temporal change of the labeling of the TCA intermediates,
present in low concentrations, can be eliminated from
the mathematical model without modifying the dynamics
of the labeling of glutamate, resulting in a 7-pools model
(Glu5
g, Glu1
g, Gln5, Gln1, Glu5
n, Glu1
n, and CO2) characterized
by five fluxes (Vtca
g , Vx
g, Vnt, Vtca
n , and Vx
n). The detailed
derivation of the labeling equations is provided in
Supplementary Appendix A.
The models were developed using Matlab (MathWorks,
Natick, MA, USA). To assess the precision and accuracy of
the different parameters, Monte-Carlo simulations of the
neuroglial model were undertaken, based on the simulated
time courses created with the complete model and
generated with the following flux values (Vtca
g = 0.06,
Vtca
n = 0.56, Vx
g =Vx
n = 0.57, and Vnt = 0.17 mmol/g per minute),
consistent with human and anesthetized rat brain (Gruetter
et al, 2001). Gaussian noise (of similar variance s2 than the
one found in experimental beta-probe data) was added to
the simulated activity curve, which was then fitted using
the different hypotheses described in the scenarios 1 to 4
(see below). Monte-Carlo simulations (500 fits) were
undertaken to estimate the uncertainty and mean value of
each flux in the different cases. The initial values of the
fluxes were taken randomly between 0 and 1 mmol/g per
minute and the values were constrained to be nonnegative.
The following four scenarios were investigated:
Case 1:
Vtca
g , Vx
g, Vnt, Vtca
n , Vx
n unconstrained.
Case 2:
Vx
g = 10Vtcag and Vxn =Vtcan .
Case 3:
as Case 2 but with 5% CBV and 11CO2 contribution added
to the simulated experimental curve. A zero weight was
given to the data points from the first 2 minutes.
Case 4:
as Case 3, but the pool of CO2 was added to the fitted
model.
In Case 3, 11CO2 production and CBV contribution were
added to the simulated tissue-activity curves but not to the
model used to fit the data. In this way, the impact of these
two additional labeling pools on the estimated fluxes could
be investigated.
In Case 4, a sensitivity analysis was also performed to
visualize the effect on the tissue curve of varying Vnt and
the composite fluxes Vgt
g and Vgt
n by steps of 10%. Vgt
g and
Vgt
n are defined as follows:
V
g
gt ¼
V
g
x V
g
tca
V
g
x þ Vgtca
and Vngt ¼
Vnx V
n
tca
Vnx þ Vntca
The neuroglial model with the assumptions used in
Case 4 was finally fitted to nine sets of AIFs and tissue
measurements obtained on different rats in resting condi-
tions, under urethane anesthesia (Wyss et al, 2009). Mean
value and uncertainty of Vnt and the composite TCA fluxes
Vgt
g and Vgt
n were estimated with Monte-Carlo simulation.
Results
Standard One-Tissue Compartment Model
First, the standard one-tissue compartment model
(Figure 1A) was fitted to the measured in vivo tissue-
activity time courses. A typical result and fit residual
are shown in Figure 1. The contribution of blood
activity to the total measured curve was largely
limited to the first 2 minutes. After this initial period,
the radioactivity originating from blood was close to
the experimental noise. For this illustrating example,
the signal contribution from blood was estimated by
the fit to be a=3.3%, and varied between 2.5% and
5% for all animals. The plot in Figure 1C clearly
shows a systematic deviation of residuals from zero,
which was consistently observed in most studies,
suggesting that the complex dynamics of brain acetate
metabolism cannot be fully described by the one-
tissue compartment model of Figure 1.
Neuroglial Model
In each case, the mean value of the different
fluxes (Vtca
g , Vx
g, Vnt, Vtca
n , Vx
n, Vgt
g , and Vgt
n ) is reported
(Table 1), as well as their s.d. (calculated from the
Monte-Carlo simulations). To check the quality
of the fit in the different treated approximations,
the fit residual and its s.d. in each case are also
indicated.
Table 2 shows the average correlations found for
the estimated fluxes in the Monte-Carlo procedure
for each case of the four.
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In the following section, we describe the results
summarized in Tables 1 and 2 for each different set of
assumptions (Cases 1 to 4).
Analysis of the Monte-Carlo Simulation for the Four
Different Cases
Case 1 (All Five Parameters Unconstrained): The
model with five free parameters presented a sig-
nificant correlation between Vtca
g and Vx
g (0.77), as
well as, to a smaller extent, between Vtca
n and Vx
n
(0.43; Table 2A), while their respective uncertain-
ties were relatively large (50% to 100%; Table 1).
However, the variance of the corresponding compo-
site fluxes Vgt
g and Vgt
n was significantly decreased
(15% and 38%, respectively). Vnt was uncorrelated
and presented an uncertainty of 73%.
Case 2 (Vx
g = 10Vtcag and Vxn =Vtcan ): Constraining Vxg
and Vx
n to reduce the uncertainty of neuronal and
glial Vtca and Vgt fluxes was without effect on the
quality of the fit compared with Case 1, as judged
from the fit residual variation, which was within 3%.
In addition, the correlation between the fitted fluxes
was reduced to < 0.43 in absolute value (Table 2B).
In Case 2, the fitted fluxes were close to the ‘true’
values (on which the Monte-Carlo simulation is
based), except for Vnt, which presented also a high
uncertainty (77%). The true Vnt value was within the
95% confidence interval of the estimated Vnt.
Case 3 (with Cerebral Blood Volume and 11CO2
Contamination in the Measured Tissue Curve): In
Case 3, where CBV and CO2 contributions were
added, the three fitted fluxes showed low correla-
tions <0.32 in absolute value (Table 2C). The uncer-
tainty of Vgt
g was particularly low (5%). Vgt
n presented
a higher uncertainty of B45%, while Vnt was over-
estimated and presented a high uncertainty ofB80%.
The omission of the two first minutes in the fitt-
ing procedure allowed keeping a good fit quality (a
fit residual 7% worse compared with Case 2) and
similar fitted values, despite the fact that blood
activity and 11CO2 contributions were not taken into
account. Vgt
g , Vnt, and Vgt
n differed from their ‘true’
value by 7%, 173%, and 16%, respectively.
Case 4 (like Case 4, CO2 Labeling Added to the
Model): In Case 4, the activity of the CO2 pool was
added to the fitted curve. A very similar fit residual
(residual 9% worse compared with Case 2), flux
values and uncertainties were found in Case 4
compared with Case 3. Vgt
g , Vnt, and Vgt
n showed a
s.d. of 5%, 79%, and 43%, respectively, diverging
from the ‘true’ value by 4%, 187%, and 13%,
respectively. These three fluxes were also well
uncorrelated (Table 2D), with the strongest correla-
tion of 0.47 between Vtcag and Vnt.
Table 1 Flux values and uncertainties determined by Monte-Carlo simulation
mmol/g
per minute
Vtca
g DVtcag Vxg DVxg Vgtg DVgtg Vnt DVnt Vtcan DVtcan Vxn DVxn Vgtn DVgtn RSS
(AU)
DRSS
(AU)
Case 1 0.314 0.354 0.424 0.370 0.048 0.007 0.455 0.332 0.507 0.274 0.476 0.275 0.189 0.072 11,902 3,139
Case 2 0.059 0.003 0.590 0.025 0.054 0.002 0.438 0.339 0.429 0.193 0.429 0.193 0.214 0.097 12,315 3,446
Case 3 0.063 0.003 0.633 0.031 0.058 0.003 0.464 0.382 0.475 0.213 0.475 0.213 0.238 0.106 13,159 3,669
Case 4 0.061 0.003 0.615 0.033 0.056 0.003 0.488 0.387 0.490 0.211 0.490 0.211 0.245 0.106 13,452 3,740
True value 0.060 — 0.570 — 0.054 — 0.170 — 0.560 — 0.570 — 0.282 — — —
Table summarizing the values and uncertainties found in the fit of the simulated data with Vtca
g =0.06, Vtca
n =0.56, Vx
g =Vx
n=0.57 and Vnt=0.17 mmol/g per
minute, under the different constraints (Cases 1 to 4) presented in Materials and methods. To enable a direct comparison between the Cases 1 to 2 and Cases 3
to 4, the residual sum of squares (RSS) was calculated starting from the second minute. The uncertainties were evaluated with Monte-Carlo simulations (500
artificial data).
Table 2 Correlation between the adjusted metabolic fluxes
Correlation Vtca
g Vx
g Vnt Vtca
n Vx
n
(A)
Vtca
g 1.00 0.77 0.11 0.01 0.01
Vx
g 0.77 1.00 0.10 0.08 0.04
Vnt 0.11 0.10 1.00 0.16 0.09
Vtca
n 0.01 0.08 0.16 1.00 0.43
Vx
n 0.01 0.04 0.09 0.43 1.00
Correlation Vtca
g Vnt Vtca
n
(B)
Vtca
g 1.00 0.43 0.37
Vnt 0.43 1.00 0.19
Vtca
n 0.37 0.19 1.00
(C)
Vtca
g 1.00 0.32 0.24
Vnt 0.32 1.00 0.22
Vtca
n 0.24 0.22 1.00
(D)
Vtca
g 1.00 0.47 0.41
Vnt 0.47 1.00 0.26
Vtca
n 0.41 0.26 1.00
Correlation of the fitted fluxes in the different simulated scenarios: (A) Case 1,
all fluxes unconstrained, (B) Case 2 (Vxg=10Vtcag and Vxn=Vtcan ), (C) Case 3
(with cerebral blood volume (CBV) and 11CO2 contamination in the measured
tissue curve), and (D) Case 4, (like Case 3, CO2 labeling added to the model).
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Sensitivity Analysis
Figure 3 shows the sensitivity analysis of the
neuroglial model to the fitted fluxes, using the
assumptions of Case 4. A typical [1-11C] acetate bolus
injection curve was considered as AIF. The analysis
was made starting from the typical flux values
already used before (Vtca
g = 0.06, Vtca
n = 0.56, Vx
g =
Vx
n = 0.57, and Vnt = 0.17 mmol/g per minute). The
thick line is the simulated curve with these para-
meters, while each thinner line represents a step
variation of 10% for the considered flux (Vgt
g in
Figure 3A, Vnt in Figure 3B, and Vgt
n in Figure 3C).
The result showed that the tissue-activity curve was
very sensitive to the glial composite flux Vgt
g . Vnt and
Vgt
n had a much smaller influence on the total brain
tissue-activity curve. The low sensitivity of the fitted
tissue curve to Vgt
n and Vnt was reflected by the
relatively large uncertainties found for these fluxes
in the Monte-Carlo study.
Experimental Data
Figure 4 shows a typical fit of an experimental tissue-
activity curve obtained with the beta-probe. The
assumptions used were those of Case 4, i.e.,
Vx
g = 10Vtcag , Vxn =Vtcan and the two first minutes of
experiment were neglected in the fit to minimize
CBV contributions to the signal. The goodness of fit
is showed by the random distribution of the residual
around zero. The experimental data correspond to
that presented in Figure 1, where the one-tissue
compartment model was fitted.
The neuroglial model was able to characterize the
time course, as no discrepancy between experimental
data and model was visible. This observation was con-
sistently made for all nine fitted experimental curves.
Figure 5 summarizes the group average and s.d. of
fluxes obtained on nine rats in resting conditions. The
mean values for Vgt
g , Vnt and Vgt
n were, respectively,
0.136±0.042, 0.170±0.103, and 0.096±0.075mmol/g
per minute (mean±s.d. of the group). The group
average of the flux uncertainties for Vgt
g , Vnt, and Vgt
n
was, respectively, 0.004±0.004, 0.052±0.069, and
Figure 3 Sensitivity analysis of the model relatively to the
parameters Vgtg (A), Vnt (B), and Vgtn (C). The thick line represents
the simulated data for (Vtcag =0.06, Vtcan =0.56, Vxg=Vxn=0.57,
and Vnt =0.17 mmol/g per minute), using a typical arterial input
function. The thinner lines represent each time a step of 10%
increase or decrease in the corresponding parameter value. The
sensitivity analysis shows that the curve is predominantly driven
by the composite flux Vgtg , characterizing the label input in the
glial glutamate C5 position.
Figure 4 Fit of the same experimental data as in Figure 3, but
using the neuroglial model with the assumption exposed in
Case 4. The fit residuals are uniformly distributed around zero.
The higher experimental values at the beginning compared with
the fit are due to the contamination of the blood activity in brain
tissue. However, thanks to the bolus injection of [1-11C] acetate,
this problem can be solved by fitting the curve starting only from
minute 2.
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0.088±0.051mmol/g per minute (mean±s.d. of the
group). Vgt
g had a reproducible value among the
different animals and its uncertainty was low in each
individual case, making it a very accurate parameter
measured in [1-11C] acetate experiments. Vnt was
measured with a typical uncertainty of B30%.
Discussion
In this study, we built a brain metabolic model for
[1-11C] acetate infusion experiments based on the
radiotracer techniques to measure tissue-activity
curves. The modeling approach was based on a two-
compartment model typically used in brain 13C-label-
ing studies. The sensitivity of the model to the involved
biochemical fluxes was assessed by fitting an artificial
tissue-activity curve, based on a typical AIF and
standard metabolic fluxes. This Monte-Carlo approach
based on the simulated data, in which the ‘true’ flux
values are known, allowed a direct assessment of the
accuracy and precision of the model under different
assumptions. Finally, using the more suitable working
assumptions, the model was successfully fitted to nine
experimental data sets acquired in vivo from adult rat
brain using a beta-probe (Wyss et al, 2009).
Measurable Fluxes: Unreliability of the Separate Vx
g
and Vtca
g Estimation
The dynamics of glial glutamate C5 labeling is
affected by the composite flux Vgt
g and by the
neurotransmission flux Vnt. Hence, Vx
g cannot be
determined separately from Vtca
g when using the
glutamate C5 curve only. The labeling dynamics of
all the metabolites labeled at C5 is symmetric to the
exchange of Vx
g and Vtca
g and all pairs of these two
fluxes resulting in a same Vgt
g will fit identically the
C5 metabolites labeling curves (Henry et al, 2006).
This underdetermination can be partially removed
by additional information coming from the C1-
labeled metabolites enrichment data. The differential
equation related to the labeling of glial glutamate C1
(Supplementary Appendix A, eq. 10) shows that Vx
g
and Vtca
g act differently on the two precursors of
glial glutamate C1 through the glial TCA cycle,
namely [1-11C] acetate and glial glutamate C5. With
a perfect tissue-activity curve, a single pair of Vx
g and
Vtca
g would fit properly the data.
However, in radiotracer experiments, the infor-
mation on C1-labeled metabolites cannot be acquired
separately. It is added to the activity from all
other labeled metabolites in the tissue. The contribu-
tion of the C1 positions to the total tissue activity
is low (Figure 4), typically < 10%. The separate
measurement of Vx
g and Vtca
g is thus unreliable, as
illustrated by the Monte-Carlo simulation for Case 1
(all fluxes unconstrained). The uncertainties of
Vx
g and Vtca
g were high and their values remained
strongly correlated.
As a consequence, it was more appropriate to fit
the experimental data by adjusting Vtca
g and con-
straining Vx
g to 10 times the value of Vtca
g , following
the results of several Nuclear Magnetic Resonance
studies (Choi et al, 2002; Gruetter et al, 1992, 2001;
Henry et al, 2002), while Vgt
g was reported. A similar
approach was used for Vtca
n and Vx
n, where Vx
n was
fixed to the value of Vtca
n . These constraints were used
for the remaining cases, i.e., 2 to 4, which affected
the quality of the fit marginally, yet improved the
precision on the remaining fluxes (Vgt
g , Vnt, and Vgt
n ).
The affinity of glial metabolism to acetate, repre-
sented by Kdil, could be theoretically extracted from
the steady-state enrichment of the glutamine labeling
positions. However, due to bolus injection of [1-11C]
acetate, a labeling steady-state was never achieved.
As a consequence, including Kdil as free parameter
was leading to a high uncertainty on its value. We
chose, therefore, to fix Kdil to the value found in
13C
MRS rat studies, in similar physiological conditions
(Duarte et al, 2011).
Glial Fluxes
With the aforementioned assumptions for Vx and Vtca
(Vx
g = 10Vtcag and Vxn =Vtcan ), the composite glial TCA
cycle flux Vgt
g was determined with high precision in
all Cases 2 to 4, with a s.d. of < 6% for Case 4. The
sensitivity of the measured tissue-activity curve
toward Vgt
g is significant (Figure 3A).
The accuracy of Vgt
g was hardly dependent on the
working assumptions studied in Cases 2 to 4, varying
from 0.054 to 0.058 mmol/g per minute for a ‘true’
Figure 5 (A) Group average and s.d. of fluxes obtained on nine
rats in resting conditions. (B) Group average of the flux
uncertainties obtained on the same nine rats. Vgtg has a
reproducible value among the different animals and its
uncertainty is low in each individual case, making it a very
accurate parameter measured in [1-11C] acetate experiments. Vnt
is measured with a typical uncertainty of B30%.
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value of 0.054mmol/g per minute. Therefore, Vgtg is a
highly reliable flux when measured with [1-11C]
acetate.
Neuronal Fluxes
Using the assumptions that Vx
g = 10Vtcag and
Vx
n =Vtca
n (Cases 2 to 4), Vtca
g , Vnt, and Vtca
n were
adjusted. Despite the goodness of fit, Vnt and Vgt
n
presented relatively high uncertainties (77% and
45%, respectively) (Table 1, Case 2) due to their low
impact on the measured curve, as seen with the
sensitivity analysis in Figures 3B and 3C. In acetate
infusion experiments, the role played by the neuro-
nal fluxes is limited to dilute the neuronal glutamate
C5 pool and by partially labeling neuronal glutamate
C1 from glutamate C5. Both of these pools have a low
activity throughout the experiment and contribute
weakly to the total measured tissue-activity curve
(Figure 4). Variations in labeling of these pools are
thus imprecisely measured.
In the experimental cases, the value of Vnt
impacted the precision of Vgt
n (data not shown): with
higher Vnt, the fractional enrichment of the neuronal
glutamate positions increased faster and the impact
of Vgt
n on the tissue-activity curve was thus stronger,
resulting in a higher precision of the fitting proce-
dure on Vgt
n . The precision of this flux was thus case
dependent.
To analyze the impact of neglecting completely the
neuronal dilution in the fit, the simulated data were
fitted with neuronal fluxes fixed to 0 mmol/g per
minute (data not shown). The fit residual was clearly
increasing (by 110% compared with Case 2, where
Vtca
n is adjusted); Vnt diverged from its real value,
while the glial fluxes were less affected by this
hypothesis. As a consequence, although poorly
determined, the neuronal fluxes Vx
n and Vtca
n should
be adjusted during the fit.
Neurotransmission Flux
Vnt converts glial glutamate-labeling positions to
glutamine and eventually to neuronal glutamate.
Since the sum of all the activity of these pools is
measured, an increase in Vnt generates a faster transit
of 11C through the glutamate-glutamine cycle, with-
out affecting significantly the shape of the total
tissue-activity curve (sum of the glutamate and
glutamine positions), as can be seen on the sensitiv-
ity analysis in Figure 3B.
As a consequence, the fitted value of Vnt had a
relatively high uncertainty compared with Vgt
g
(Table 1, Cases 1 to 4). In Case 4, Vnt was not strongly
correlated with the neuronal and glial TCA cycle
fluxes and has therefore low impact on the value
found for Vgt
g and Vgt
n (Table 2D).
Blood Partial Volume
As shown in the decomposition of the total tissue-
activity curve in Figure 4, the tissue pool dominating
the total labeling in the first minutes is glutamate C5.
From its labeling equation (Supplementary Appen-
dix A, eq. 9), it can be seen that the slope of gluta-
mate C5 labeling at early time points is equal to
Vgt
g Kdil. As already mentioned in the case of the
one-tissue compartment model, the activity contri-
bution due to blood partial volume effect in the
measured voxel is mainly limited to the first
2 minutes: fitting the complete tissue-activity curve
with a variable blood partial volume would lead to a
strong correlation between Vgt
g and the blood partial
volume, since both are closely related to the first
points of the tissue-activity curve (data not shown).
These points have also the lowest signal-to-noise
ratio of the experiment. As a consequence, CBV
values can only be unreliably extracted from the
fitting procedure. Likewise, assuming a standard
brain blood partial volume value may depend on the
position of the probe in the brain and might vary
between animals leading to biased Vgt
g values.
Therefore, it was preferred to neglect the first
2 minutes of data following the 11C bolus injection
and to neglect the blood partial volume contribution.
As a matter of fact, in the simulations of Cases 3 and
4, a 5% blood partial volume contribution was added
to the simulated total tissue curve, while the model
was fitted starting after the second minute without
taking into account the blood contamination.
Table 1 Case 3 (with CBV contamination) compared
with Case 2 (without CBV contamination) shows
that blood contamination of the signal resulted in a
slight increase in the fit residual, while this working
assumption minimally affected the value and
precision of the adjusted fluxes ( < 8% for Vtca
g , Vx
g,
and Vnt and 11% for Vtca
n and Vx
n). In Case 3, CBV and
11CO2 contributions were added simultaneously, to
avoid the generation of too many scenarios in
the fitting assumptions. Adding only the CBV
contribution to the simulated data resulted in similar
fluxes values, uncertainties and correlations (not
shown).
Inclusion of the CO2 Labeling in the Model
In Case 3, the labeling of CO2 was also added to the
simulated tissue-activity curve but not to the model
used. As discussed above regarding the CBV con-
tribution, the fitted flux values were minimally
affected by this additional contribution. Adding the
CO2 pool without the CBV contribution to the
simulated tissue-activity curve led to the same
observation (not shown). This is consistent with
the low activity of 11CO2 compared with the total
tissue activity observed in the fits of the experi-
mental data (Figure 4). As a consequence, the
contribution of CO2 to total tissue activity can be
considered negligible.
Adding the CO2 pool to the fitted model (Case 4)
had a positive impact especially on Vgt
g , whose value
was getting closer to the ‘true’ value used for the
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simulation. Adding the pool of CO2 in the model is,
therefore, desirable to obtain unbiased quantification
of the glial TCA cycle activity, which is the most
precisely determined flux of this neuroglial model
when using 11C-acetate beta-probe data. For these
reasons, the assumptions used in Case 4 were further
used to fit the experimental data and are proposed in
general to fit the model presented here to [1-11C]
acetate brain studies.
Fluxes Derived from the Experimental In Vivo Data
The model was fitted to nine tissue-activity curves
with corresponding AIFs (Figure 4). The consistently
uniform distribution of the residuals around zero
reflects the good quality of the fit of the model. The
precision on Vgt
g , Vnt, and Vgt
n obtained with the fit of
the experimental data with the neuroglial model
were of the same order as the results of the Monte-
Carlo simulations.
In the experimental results, the group average Vgt
n
is as large as the corresponding group s.d.
(Vgt
n = 0.10 mmol/g per minute, DVgtn = 0.09 mmol/g per
minute). Therefore, we conclude that Vgt
n cannot be
reliably extracted from the fit. For Vnt, the average
uncertainty isB30% of the flux value, which makes
it a less sensitive flux in [1-11C] acetate infusion
studies, compared with Vgt
g . The average Vnt is in
good agreement with the values found in 13C MRS
studies (de Graaf et al, 2003a; Sibson et al, 1997,
2001; Duarte et al, 2011).
Vgt
g , characterizing glial oxidative metabolism, can
be reliably and reproducibly determined with this
protocol of [1-11C] acetate infusion. The average Vgt
g is
comparable to the literature values found in 13C MRS
studies (de Graaf et al, 2003a; Sibson et al, 2001;
Duarte et al, 2011). In some studies, Vx (assumed
identical in the neuronal and glial compartments)
was found to be significantly bigger than Vtca
g . In
this case, the composite flux Vgt
g is almost equal to
Vtca
g . The average Vgt
g found in the present study
was, therefore, compared with the values of Vtca
g of
these studies.
The experimental precision on Vgt
g found in this
study is comparable or even higher than those found
with 13C MRS in the literature. The comparison
with 13C glucose infusion experiments should be
performed with care, since the value found in these
cases for Vtca
g might be subject to high uncertainties
(Shestov et al, 2007). Glucose being metabolized
both on the neuronal and glial sides and Vtca
n being
typically five times bigger than Vtca
g , the labeling of
glutamate is mainly reflecting neuronal activity and
the data obtained in glucose 13C MRS studies are
much less sensitive to glial metabolism.
In the glial compartment, pyruvate carboxylation
affects the position C1 of glial glutamate, as an
additional dilution flux, in the second turn of the
TCA cycle. However, the C1-labeling positions have
a low contribution to the total tissue-activity curve
(Figure 4); and therefore, pyruvate carboxylation
affects marginally the 11C tissue uptake curves.
Fitting a tissue-activity curve generated with the
inclusion of pyruvate carboxylation, but fitted with
the presented model had negligible impact on the
derived metabolic fluxes Vgt
g , Vnt, and Vgt
n (data not
shown). The pyruvate carboxylation pathway was,
therefore, neglected in this model.
The flux Vgt
g determined with the neuroglial
model has a similar role as the uptake parameter K1
of the previously applied one-tissue compartment
model. However, the dynamics of 11C release from
brain tissue is more complex and requires the
modeling of the neuroglial interaction. The gluta-
mate-glutamine cycle is buffering 11C, storing the
label temporarily before its release as 11CO2 from the
glial or neuronal TCA cycle. This delayed 11C release
was already noticed with the one-tissue compart-
ment model. k2 was decreasing significantly
when fitting only the first 5 minutes of the uptake
curve compared with the fit of the complete curve
(Wyss et al, 2009).
Compared with 13C MRS, the determination of glial
oxidative metabolism with [1-11C] acetate infusion
and positron emission measurements has several
advantages. First, the high sensitivity of radiotracer
detection enables measuring glial metabolism under
physiological conditions due to trace amounts of
[1-11C] acetate infusion (B0.5 nmol). Second, the
experiment can be realized in only 20 to 30 minutes,
while 13C MRS studies, with a typical time resolution
of 10 minutes, need at least 2 to 3 hours of
acquisition. The spatial resolution of this technique
(B8mL with beta-probe) is higher than what can be
achieved with 13C MRS, thanks to the high sensitivity
of positron emitter detection.
Using a PET scanner instead of the beta-probe
would allow whole brain coverage in a single
experiment with less impact on brain tissue, while
obtaining similar or better spatial resolution. A
cerebral mapping of Vgt
g is therefore conceivable,
provided a nearby cyclotron is available.
However, the absence of chemical information on
the molecule emitting the positron reduces the
number of determined metabolic fluxes compared
with 13C MRS. The precise measurement of the AIF
and its correction is an important step of the
measurement to obtain accurate results and is
probably the most limiting factor.
Like in 13C MRS studies, a measurement of the
total plasma acetate is also necessary to further
extract the fractional enrichment of acetate, the
precursor of all the modeled pools. However, in
[1-11C] acetate studies, one single measurement
should be enough since the injection of the tracer
is negligible compared with the natural plasma
acetate concentration, which should therefore not
vary significantly during the experiment. The
requirement is thus similar to an 18FDG study, in
which the plasma glucose concentration is needed
for quantification.
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Conclusion
We conclude that the presented new model for
in vivo brain metabolic studies using [1-11C] acetate
infusion is able to describe the kinetics in 11C-acetate
radiotracer as well as 13C-acetate MRS experiments,
allowing to estimate Vgt
g and Vnt for the rat in < 30
minutes.
We further conclude that radiotracer experiments
using [1-11C] acetate infusion can be used for the
study of local glial oxidative metabolism. Minimal
invasiveness and short acquisition periods make it
an interesting method for human—possibly clini-
cal—PET applications.
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